Review: Central & Peripheral Nervous System: Cholecystokinin-B receptor antagonists

References

• MUTT V: Cholecystokinin: Isolation, Structure and Functions. in Gastrointestinal Hormones. pp 169–221. Glass, GBJ (Ed) New York, Raven Press.
   Google Scholar
• EVANS BE, BOCK MG: Promiscuity in Receptor ligand research: Benzodiazepine-based cholecystokinin an-tagonists. Adv. Med. Chem. (1993) 2: 111–152.
   Google Scholar
• This is an excellent review of the original discovery of the ben-zodiazepine CCK antagonists and their role in characterisation of CCK pharmacology.
   Google Scholar
• HARRO J, VASAR E, BRADWEJN J: CCK in animal and human research on anxiety. Tr. Pharmacol. Sci. (1993) 112: 452–454
   Google Scholar
• DOOLEY DJ, KLAMT I: Differential profile of the CCK-Breceptor antagonist C1-988 and diazepam in the four-plate test. Psychopharmacol. (1993) 112: 452–454
   Google Scholar
• RASMUSSEN K, CZACHURA JF, STOCKTON ME, HOWBERT n Electrophysiological effects of diphenylpyrazolidine cholecystokinin-A antagonists on m1dbrain dopamine neurons. J. Pharmacol. Exp. Ther. (1993) 264: 480–488.
   PubMedGoogle Scholar
• NOBLE F, DERRIEN M, ROQUES BP: Modulation of opioid antinociception by CCK at the supraspinal level: evi-dence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Phar-macol (1993) 109: 1064–1070.
   PubMedGoogle Scholar
• BRADWEJN J, KISZYCKI D, COUETOLTX DU It. IRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, ANNABLE L: The panicogenic effects of cholecystokinin-tetrapeptide are antagonised by L-365,260, a central cholecystokinin receptor. Archives of General Psychiatry (1994) 51: 486–493
   Google Scholar
• CHEN I-W, DORLEY JM, RAMJIT HG, PITZENBERGER SM, LIN JH: Physiological disposition and metabolismof L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab. and Dispo-sition. (1992) 20: 390–395.
   PubMedGoogle Scholar
• MAKOVEC F: CCK-B/gastrin-receptor antagonists. Drugs Future (1993) 18: 919–931.
   Google Scholar
• Excellent reviews of the CCK-B area.
   Google Scholar
• BOCK M, DIPARDO RM, EVANS BE, RITTLE ICE, WHITTIER WL, GARSICY VM, GILBERT ICF, LEIGHTON JL, CARSON KL, MELLIN EC, VEBER DF, CHANG RSL, LOTTI VJ, FREEDMAN SB, SMITH AJ, PATEL S, ANDERSON PS, FREIDINGER RM: Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J. Med. Chem. (1993) 36: 4276–4292.
   PubMed Web of Science ®Google Scholar
• CHAMBERS MS, HOBBS SC, FLETCHER SR, MATASSA VG, MITCHELL J, wATr AP, BAKER R, FREEDMAN SB, PATEL S, SMITH AJ: L-708,474: The C5-cyclohexy; analogue of L-365,260, a selective high affinity ligand for the CCK-B-gastrin receptor. Bioorg. Med. Chem. Len. (1993) 3: 1919–1924.
   Web of Science ®Google Scholar
• A description of the SAR of new C-5 substituted benzodiazepine CCK-B antagonists.
   Google Scholar
• NISHIDA A, MIYATA K, TSUTSUMI R, YUICI H, AKUZAWAS, KOBAYASHI A, KAMATO T, ITO H, YAMANO M, ICATUYAMA Y, SATOH M, OHTA M, HONDA K: Pharma-cological profile of (R)-1-(2,3-dihydro-1(2"-methyl-phe nac y1)- 2-oxo-5-phenyl- 1H-1,4-benzodi azepin-3-y1)-3-(3-methylphenyDurea (YM022) a new potent and selective gastrin-cholecystokinin -B recep-tor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. (1994) 269(2): 725–731.
   PubMedGoogle Scholar
• NISHIDA A, TAKINAMI Y, YUKI H, KOBAYASHI A, AKUZAWA S, ICAMATO T, ITO H, YAMANO M, NAGAKURA Y, MIYATA K: YM022 aR)-1-(2,3-dihydro-1-(2"methyl-phenacy1)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-y1)-3-(3-methylphenyOurea), a potent and selective gastrin- lesions in rats. J. Pharmacol, Exp. Ther. (1994) 270(3): 1256–1261.
   PubMedGoogle Scholar
• BOCK MG, DIPARDO RM, VEBER DF, CHANG RSL, LOTTIVJ, FREEDMAN SB, FREIDLINGER RM,: Benzolactams as nonpeptide cholecystokinin receptor ligands. Biootg Med. Chem, Lett. (1993) 3: 871–874.
   Web of Science ®Google Scholar
• LOWE III JA, HAGEMAN DL, DROZDA SE, MCLEAN S, BRYCE DK, CRAWFORD RT, ZORN S, MORRONE J, BORD-NER J: 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. J. Med. Chem. (1994) 37: 3789–3811.
   PubMed Web of Science ®Google Scholar
• LOWE III JA, QIAN W, SCOTT PJ, MCLEAN S, BRYCE DK,CRAWFORD RT, BORDNER J: 5,7- Dipheny1-3-ureidohexahydroazepin-2-ones as cholecystokinin-B recep-tor ligands. Bioorg. Med. Chem. Lea. (1994) 4(24): 2877–2882.
   Google Scholar
• HORWELL DC, HUGHES J, HUNTER JC, PRITCFIARD MC, RICHARDSON RS, ROBERTS E, WOODRUFF GN: Rationally designed "dipeptoid" ananlogues of CCK: a-methyltryp-tophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. I Med. Chem. (1991) 34: 404–414.
   PubMed Web of Science ®Google Scholar
• The primary disclosure of the discovery of the "dipeptoid" CCK receptor antagonists.
   Google Scholar
• HIGGINBOTTOM M, HORWELL DC, ROBERTS E: Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class. Bioorg. Med. Chem. Lett. (1993) 3: 881–884.
   Google Scholar
• DRYSDALE MJ, PRITCHARD MC, HORWELL DC: The syn-thesis and CCK receptor affinities of selected carboxylic acid mimics of CI-998 - a potent and selective CCK-B antagonist. Bioorg. Med. Chem. Lett. (1992) 2(1): 45–8.
   Google Scholar
• HIGGINBOTTOM M, HILL DR, HORWELL DC, MOSTAFAI E, SUMAN-CHAUHAN N, ROBERTS E: Conformationally re-stricted analogues of the potent CCK-B antagonist CI-988. Bioorg. Med. Chem. (1993) 1(3): 209–17.
   PubMedGoogle Scholar
• DAVEY AE, HORWELL DC: Modification of "peptoid" CCK-B antagonists to probe requirements for CCK-B agonist activity. Bioorg. Med. Chem. (1993) 1(1): 45–58.
   PubMedGoogle Scholar
• GUYON C, DUBROEUCQ MC, BARREAU M, BERTRAND P, BOEHME GA: Ureido-acetamides (1II): synthesis of opti-cally active derivatives. XXIth International Symposium on Medicinal Chemistry. Basel, Switzerland, (1992) Poster #P–186.C.
   Google Scholar
• BERTRAND P, BOHME GA, DURIEUX C, GUYON C, CAPET M, JEANTAUD B, BOUDEAU P, DUCOS B, PENDLEY CE, MARTIN GE, FLOCH A, DOBLE A: Pharmacological prop-erties of ureido-acetamides, new potent and selective non-peptide CCK-B/gastrin receptor antagonists. Eur.J. Pharmacol. (1994) 262: 233–245.
   PubMed Web of Science ®Google Scholar
• HOWBERT JJ, LOBB KL, BRrrroN TC, MASON NR, BRUNSRF: Diphenylpyrazolidinone and Benzodiazepine Cholecystokinin Antagonists: A Case of Convergent Evolution in Medicinal Chemistry. Bioorg. Med. Chem. Lett. (1993) 3: 875–880.
   Web of Science ®Google Scholar
• YU MJ, THRASHER J, MCCOWAN JR, MASON NR, MENDEL-SOHN LG: Quinazolinone Cholecystokinin-B receptor Ligands. J. Med. Chem (1991) 34:1505–1508.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN K, CZACHURA JF, STOCKTON ME, HOWBERT JJ: Electrophysiological effects of diphenylpyrazolidi-none cholecystokinin-B and cholecystokinin -A antago-nists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. (1993) 264(1): 480–8.
   PubMedGoogle Scholar
• RASMUSSEN K, MCQUALD LA, STOCKTON ME: The CCK-Bantagonist. LY288513 blocks some behavioural effects of MK-801 and phencyclidine (PCP). 23rd Annual Meet-ing of the Society for Neuroscience, Washington D.C., USA. November (1993) 19(1–3): 172.
   Google Scholar
• OHTSUKA T, KUDOH T, SHIMMA N, KOTAKI H, NAKAYAMA N, ITEZONO Y, FUJISAIU N, WATANABE J, YOKOSE K, SETO H: Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced byStreptonsyces sp. J. Antibiot. (1992) 45: 140–143.
   PubMedGoogle Scholar
• LAM YKT, BOGEN D, CHANG RS, FAUST KA, HENSENS HB:Novel and potent gastrin and cholecystokinin antago-nist from Streptonsyces olivaceus. J. Antibiot. (1991) 44: 613–625.
   PubMedGoogle Scholar